Also from the Wall Street Journal, we learn here that Emory’s defense of Nemeroff’s undisclosed hundreds of thousands from GSK is that some of the payments were not for promotional talks, but for “CME-like” talks.
Nobody seems to have an inkling what "CME-like" means. But after reading through Nemeroff's Effexor Love-fest supplement, I'm getting an idea.
Here is how Dr. Nemeroff introduces the supplement:
“There is little doubt that the introduction of venlafaxine has had a remarkable impact on clinical practice. I have had more than 25 patients who have failed multiple trials with virtually all of the antidepressants available who have responded to venlafaxine often with complete remission.”
And here are some random phrases culled from the abstracts of the 13 other CME-like articles, done up in Wyeth's green and purple Effexor color scheme:
Venlafaxine is a unique antidepressant medication with well documented efficacy and safety in the acute treatment of major depressive disorder
easy to monitor and dose
may also be effective in the treatment of dysthymic disorder and bipolar II depression
facilitate successful treatment of patients.
easy to monitor and dose
may also be effective in the treatment of dysthymic disorder and bipolar II depression
facilitate successful treatment of patients.
low potential for drug interactions
appropriate first-line medication for GAD
may be particularly effective for the severely ill
good tolerability
may be effective for conditions such as stroke, anxiety, and neuropathic pain
may be useful in children and adolescents with a variety of psychiatric disorders
effective in reducing anxiety in patients with depression
efficacy...in several other conditions including panic disorder, social anxiety disorder, obsessive compulsive disorder, trichotillomania, ADHD, chronic pain, and fibromyalgia
an attractive choice for geriatric patients
may be particularly effective for the severely ill
good tolerability
may be effective for conditions such as stroke, anxiety, and neuropathic pain
may be useful in children and adolescents with a variety of psychiatric disorders
effective in reducing anxiety in patients with depression
efficacy...in several other conditions including panic disorder, social anxiety disorder, obsessive compulsive disorder, trichotillomania, ADHD, chronic pain, and fibromyalgia
an attractive choice for geriatric patients
So here is a working definition of CME-like:
--Too academic-sounding to be an advertisement
--Too commercially biased to be CME
--Ergo...it's CME-like!
2 comments:
An "Unrestricted Educational Grant" from a pharmaceutical company MUST be disclosed to readers. If there is no disclosure in this supplement, as you say, then this is a very serious violation of FDA regulations and will have serious consequences for the sponsor. Is it possible that the journal publisher's made a mistake and left the disclaimer off the supplement?
Hmmm, no mention of the nasty withdrawal potential.
Post a Comment